CRF1 Receptors
The corticotropin-releasing factor (CRF) 1 receptor is a member of the corticotropin-releasing factor family of G-protein-coupled receptors that also includes CRF2. It is abundantly expressed in the CNS, with major expression in the cortex, cerebellum, hippocampus and amygdala.
CRF1 Receptor Agonists |
|
---|---|
Cat. No. | Product Name / Activity |
1608 | Stressin I |
CRF1 agonist | |
CRF1 Receptor Antagonists |
|
Cat. No. | Product Name / Activity |
2778 | Antalarmin hydrochloride |
CRF1 antagonist | |
2779 | CP 154526 |
Selective, non-peptide CRF1 antagonist | |
3212 | CP 376395 hydrochloride |
Potent and selective CRF1 antagonist; binds at an allosteric site | |
1591 | NBI 27914 hydrochloride |
Selective non-peptide CRF1 antagonist | |
3100 | NBI 35965 hydrochloride |
Potent and selective CRF1 antagonist | |
6451 | Pexacerfont |
Potent and selective CRF1 antagonist; anxiolytic | |
6530 | R 121919 hydrochloride |
High affinity CRF1 antagonist; orally bioavailable |
The corticotropin-releasing factor (CRF) 1 receptor is a member of the corticotropin-releasing factor family of G-protein-coupled receptors that also includes CRF2. It is abundantly expressed in the CNS with major expression in the cortex, cerebellum, hippocampus, amygdala, olfactory bulb and pituitary. In the periphery the receptors are expressed at low levels in the skin, ovary, testis and adrenal gland.
External sources of pharmacological information for CRF1 Receptors :
Literature for CRF1 Receptors
Tocris offers the following scientific literature for CRF1 Receptors to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.